Management of Alloimmunization During Pregnancy
Publication Date: March 1, 2018
Last Updated: March 14, 2022
Recommendations
In a center with trained personnel and when the fetus is at an appropriate gestational age, Doppler measurement of peak systolic velocity in the fetal middle cerebral artery is an appropriate noninvasive means to monitor pregnancies complicated by red cell alloimmunization. (A)
574
The initial management of a pregnancy involving an alloimmunized patient is determination of the paternal erythrocyte antigen status. (A)
574
Serial titers are not useful for monitoring fetal status when the mother has had a previously affected fetus or neonate. (A)
574
Antibody titers are not appropriate for monitoring Kell-sensitized patients because Kell antibodies do not correlate with fetal status. (A)
574
Anti-D immune globulin is indicated only in Rh-negative women who are not previously sensitized to D. (A)
574
Recommendation Grading
Disclaimer
Overview
Title
Management of Alloimmunization During Pregnancy
Authoring Organization
American College of Obstetricians and Gynecologists
Publication Month/Year
March 1, 2018
Last Updated Month/Year
January 9, 2023
Document Type
Consensus
External Publication Status
Published
Country of Publication
US
Inclusion Criteria
Female, Adolescent, Adult
Health Care Settings
Ambulatory
Intended Users
Physician, nurse midwife, nurse, nurse practitioner, physician assistant
Scope
Management
Diseases/Conditions (MeSH)
D011250 - Pregnancy Complications, Hematologic, D011248 - Pregnancy Complications, D000078422 - Allogeneic Cells, D011259 - Pregnancy Tests, Immunologic, D011252 - Pregnancy Complications, Neoplastic
Keywords
Alloimmunization, maternal antibodies